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Inhibiting avian influenza virus shedding 
using a novel RNAi antiviral vector technology: 
proof of concept in an avian cell model
Lyndsey M. Linke1,2*, Jeffrey Wilusz3, Kristy L. Pabilonia1,3, Johannes Fruehauf4, Roberta Magnuson1,2, 
Francisco Olea‑Popelka2, Joni Triantis1,2,5, Gabriele Landolt2 and Mo Salman1,2
Abstract 
Influenza A viruses pose significant health and economic threats to humans and animals. Outbreaks of avian influenza 
virus (AIV) are a liability to the poultry industry and increase the risk for transmission to humans. There are limitations 
to using the AIV vaccine in poultry, creating barriers to controlling outbreaks and a need for alternative effective con‑
trol measures. Application of RNA interference (RNAi) techniques hold potential; however, the delivery of RNAi‑medi‑
ating agents is a well‑known obstacle to harnessing its clinical application. We introduce a novel antiviral approach 
using bacterial vectors that target avian mucosal epithelial cells and deliver (small interfering RNA) siRNAs against two 
AIV genes, nucleoprotein (NP) and polymerase acidic protein (PA). Using a red fluorescent reporter, we first demon‑
strated vector delivery and intracellular expression in avian epithelial cells. Subsequently, we demonstrated significant 
reductions in AIV shedding when applying these anti‑AIV vectors prophylactically. These antiviral vectors provided up 
to a 10,000‑fold reduction in viral titers shed, demonstrating in vitro proof‑of‑concept for using these novel anti‑AIV 
vectors to inhibit AIV shedding. Our results indicate this siRNA vector technology could represent a scalable and clini‑
cally applicable antiviral technology for avian and human influenza and a prototype for RNAi‑based vectors against 
other viruses.
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Introduction
Avian influenza virus (AIV) outbreaks in poultry have led 
to the global culling of millions of birds and the net loss 
of billions of dollars. These outbreaks are of concern, not 
only because of the degree of virulence observed in poul-
try resulting in severe economic consequences, but also 
due to the potential transmission to mammalian species, 
including humans.
Effective prevention measures must be available to pre-
pare for potential outbreaks, however, current vaccina-
tion strategies for birds are limited. The most efficacious 
vaccines must be administered subcutaneously or intra-
muscularly (Halvorson 2008; Rudolf et  al. 2010; Swayne 
2012), an impediment to successfully immunizing large 
numbers of poultry in a short period. In the naïve bird, 
protective antibody production takes two to 3  weeks 
to acquire following vaccination (Kim et  al. 2009). Fre-
quently, improper storage and handling leads to vaccine 
failure (Swayne and Kapczynski 2008). To elicit efficient 
protection, the vaccine must be HA-subtype specific to 
the outbreak virus (Arzt et  al. 2010; Bennink and Pal-
more 2004; Escorcia et al. 2008; Swayne 2012; Zhou et al. 
2008). Over time, stockpiles of vaccines become obsolete 
and new vaccines must be generated. These limitations 
convey a genuine need to develop a prophylactic that 
would offer universal protection against any subtype or 
strain of AIV and would provide rapid protection in the 
face of an outbreak.
Using RNAi to develop antivirals has created a wealth 
of research focused on controlling diseases using siRNAs 
(Barik and Lu 2015; Chen et al. 2009; DeVincenzo 2012; 
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Long et al. 2010; Lyall et al. 2011; Shi et al. 2012). Oth-
ers have previously demonstrated that siRNA mediated 
knockdown targeting both the viral NP and PA genes 
significantly inhibits influenza replication (Ge et al. 2004; 
Khantasup et  al. 2014; Stoppani et  al. 2015; Tompkins 
et  al. 2004; Zhou et  al. 2007, 2008). However, the chal-
lenge of intracellular delivery of these RNAi-mediating 
agents has historically been an obstacle to harnessing 
their capabilities and clinical application (Li and Shen 
2009). SiRNAs require a delivery vehicle, and two exam-
ples are genetically engineered viruses and synthetic car-
riers (Aigner 2009; DeVincenzo 2012; Ge et  al. 2004; Li 
et al. 2006). However, these viral delivery vectors can pose 
significant concerns for clinical efficacy, including associ-
ated hepatotoxicity and tumorigenesis (Beer et  al. 2010; 
Davidson and McCray 2011; Ge et al. 2004; Grimm et al. 
2006; Hacein-Bey-Abina et  al. 2008). Past reports warn 
of off-target effects from short hairpin RNA (shRNA) 
viral vectors resulting in cell death and organ problems in 
transgenic animals (Grimm et al. 2006). Finally, synthetic 
siRNA carriers have low delivery efficiencies and require 
higher doses, which is not only cost prohibitive, but often 
toxic (DeVincenzo 2012; Ge et al. 2004).
The aim of this study was to investigate the inhibition 
of AIV shedding in avian epithelial cells using the RNAi 
delivery platform, transkingdom RNAi (tkRNAi). TkR-
NAi uses nonpathogenic E. coli engineered to transcribe 
shRNA from a plasmid (pmbv43) that also encodes two 
factors allowing shRNA delivery to mucosal epithelial 
cells; the invasin gene (Inv) and the listeriolysin O gene 
(hylA). The Inv gene is necessary for expression of invasin 
protein on the E. coli surface (Xiang et  al. 2006), which 
interacts with β(1) integrin receptors present on mucosal 
epithelial cells resulting in receptor mediated endocy-
tosis (Conte et  al. 1994; Isberg and Barnes 2001; Isberg 
and Leong 1990). The hlyA gene encodes a pore-forming 
toxin that facilitates the rupture of the endosomal mem-
brane and the subsequent release of shRNA into the 
cell’s cytoplasm (Grillot-Courvalin et  al. 1998; Mathew 
et  al. 2003; Nguyen and Fruehauf 2009; Radford et  al. 
2002; Xiang et  al. 2006). The tkRNAi vector is a diami-
nopimelic acid (Dap) auxotrophic mutant and is kanamy-
cin resistant.
Figure  1 provides a diagrammatic picture of the anti-
AIV vector’s mechanism of action in an avian epithelial 
cell and its ability to inhibit infectious AIV shedding. We 
designed tkRNAi vectors (anti-AIV vectors) that consti-
tutively generate shRNAs targeting conserved sequences 
within the NP and PA viral genes, with the purpose to 
demonstrate in  vitro proof-of-concept for using these 
anti-AIV vectors to inhibit AIV shedding in an avian cell 
model. These anti-AIV vectors would offer several advan-
tages over conventional AIV vaccines and improve upon 
existing RNAi antiviral approaches for several reasons. 
These vectors are engineered to target mucosal epithe-
lium, so are ideal for targeted delivery aimed at prevent-
ing respiratory diseases. As non-conjugative vectors, they 
will not integrate into the host genome, eliminating the 
risk for tumorigenesis. Furthermore, the tkRNAi plat-
form has a confirmed safety record for clinical purposes 
(Nguyen and Fruehauf 2009; Xiang et  al. 2006, 2009), 
and as non-conjugative, non-pathogenic and non-colo-
nizing bacteria, do not pose any known risk to the host. 
Although these vectors target viral sequences that have 
high levels of conservation observed over time and geo-
graphic location to limit the risk for viral escape, they 
can be quickly adapted to respond to viral mutation. 
Unlike conventional vaccines, this antiviral vector would 
reduce trade barriers associated with reactivity of vac-
cinated animals because animals would not test positive 
for AIV antibodies. These vectors could be administered 
intranasally, orally, or as an aerosol suitable for inhala-
tion. Finally, these anti-AIV vectors could be generated 
in a scalable process for low-cost production, stock-




Chicken primary hepatocellular carcinoma epithelial 
(LMH) cells (ATCC CRL-2117) were maintained in Way-
mouth’s MB 752/1 medium (Life Technologies, Carls-
bad, USA), with 10 % heat inactivated fetal bovine serum 
(FBS), 2  mM  l-glutamine, 100  Units/mL penicillin and 
1  mg/mL streptomycin (Life Technologies), and unless 
stated otherwise, incubated at 37  °C in the presence of 
7 % CO2. All LMH culture vessels were pre-coated with 
0.1  % gelatin (EMD Millipore Corporation, Billerica, 
USA). Madin-Darby canine kidney (MDCK) cells (ATCC 
CCL-34) were used to quantify infectious viral titers for 
all infection assays. MDCK cells were grown in minimum 
essential medium with Earle’s balanced salts (MEM/
EBSS), 2 mM l-glutamine, 10 % FBS, 0.5 % sodium pyru-
vate (100  mM solution, Life Technologies), 0.5  % MEM 
non-essential amino acids (NEAA) (100 × solution, Life 
Technologies), and 100 Units/mL penicillin and 1 mg/mL 
streptomycin at 37 °C in the presence of 7 % CO2.
A/chicken/Texas/473-2/2010(H6N2) and A/turkey/
Colorado/235497/2003(H8N4) were propagated in LMH 
cells. H6N2 and H8N4 strains represented two AIV sub-
types isolated from poultry and previously replicated to 
high titers in LMH cells with visual cell damage indica-
tive of a cytopathic effect (CPE) at 48  h post infection 
(hpi). CPE was defined as observed destruction of the cell 
monolayer after fixing and staining cells with crystal vio-
let. Viral stocks were generated in LMH cells and stored 
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at −80  °C. Working virus stocks and all experimentally 
derived virus titers were measured by 50 % tissue culture 
infectious dose (TCID50) assay in MDCK cells. Optimal 
multiplicity of infection (MOI) was empirically derived 
based on the lowest MOI that produced CPE in LMH 
cells within 48 hpi.
Construction of shRNA vectors
Sense and antisense RNA sequences for NP and PA were 
previously published (Ge et  al. 2003), and were used to 
construct appropriate shRNAs. Using the BLAST heu-
ristic algorithm to find the degree of sequence align-
ment, siRNA sense strand complementarity to the NP 
and PA viral gene sequences associated with H6N2 and 
H8N4 were verified. The NP and PA siRNA sequences 
both aligned against the corresponding NP and PA 
sequences from H8N4 and H6N2 subtypes with 100  % 
identity (Table  1). GenBank accession numbers for the 
NP and PA viral genes are given in Table 2. To decrease 
the possibility of off-target silencing, both 19 nt siRNA 
sequences were analyzed by BLAST search to ensure 
a lack of significant sequence complementarity to any 
known chicken gene sequence. A key feature of siRNA 
recognition involves perfect complementary base pairing 
between the siRNA seed region (nucleotides 2–8) on the 
antisense 5′ end and the mRNA target gene (Carthew and 





Fig. 1 Diagrammatic representation of the anti‑AIV vector’s mechanism of action against AIV in an avian epithelial cell
Table 1 Top sense-strand sequence of  NP and  PA siRNAs, 
the location of  the target sequence in  the corresponding 
NP or PA virus gene and siRNA specificity with the original 
AIV gene
Gene (bp region) Sense strand sequence (5′–3′)
NP‑siRNA GGA TCT TAT TTC TTC GGA G‑dTdT
H8N4 NP (1486–1504) GGA TCT TAT TTC TTC GGA G
H6N2 NP (1453–1471) GGA TCT TAT TTC TTC GGA G
PA‑siRNA GCA ATT GAG GAG TGC CTG A‑dTdT
H8N4 PA (2077–2095) GCA ATT GAG GAG TGC CTG A
H6N2 PA (2065–2083) GCA ATT GAG GAG TGC CTG A
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Sontheimer 2009; Ma et  al. 2005; Martinez et  al. 2002). 
As such, 100  %  complementarity between the siRNA 
seed region and an mRNA chicken gene was deemed 
unacceptable. 
The shRNA expression plasmid, pmbv43, has been pre-
viously described (Buttaro and Fruehauf 2010). A total 
of 2 µg parent/pmbv43 plasmid (provided by Cambridge 
Biolabs, Cambridge, USA) was digested and subsequently 
treated with Alkaline Phosphatase, Calf intestinal (New 
England Biolabs, Ipswich, USA) and phenol/chloroform 
and ethanol precipitated. The resulting 8.4 kb linear par-
ent/pmbv43 plasmid was gel extracted and isolated using 
dialysis.
The DNA template encoding the shRNA specific 
for NP and PA was: BamHI site-sense sequence-hair-
pin loop (5′-TTC AAG AGA-3′)-antisense sequence-
TTTTTTTTTT-SalI site. Using standard cloning and 
plasmid purification methods, the NP/pmbv43 plasmid 
was commercially synthesized and purified (DNA2.0 Inc., 
Menlo Park, USA). Both strands of the PA DNA oligonu-
cleotide sequence were commercially synthesized (Inte-
grated DNA Technologies, Coralville, USA) and the PA/
pmbv43 plasmid was generated in-house. The PA oligo-
nucleotides were annealed, phosphorylated, and ligated 
into the linear pmbv43 plasmid. The resulting ligation 
mixture was transformed into DH5α competent cells and 
plated onto Luria Broth (LB) plates containing 10 µg/mL 
kanamycin (Kan). After incubating overnight, resulting 
colonies were screened by PCR. A single PCR positive 
PA/pmbv43 plasmid clone was purified using the Pure-
Link HiPure Plasmid Maxiprep Kit (Life Technologies) 
and sequenced to verify proper PA/shRNA insertion.
NP/pmbv43, PA/pmbv43, and parent/pmbv43 were 
each transformed into CEQ221 competent E. coli cells 
(provided by Cambridge Biolabs) and plated onto 
Brain Heart Infusion (BHI) agar containing 25 µg/mL 
Kan and 50  µg/ml 2,3-Diaminopropionic Acid (BHI/
Kan/Dap). Resulting colonies were screened by PCR, 
and for each, a single positive clone was sequence 
validated and propagated. Stocks were generated 
(OD600 = 1.0) and frozen back at −80 °C in 20 % glyc-
erol. A single frozen aliquot from each vector stock 
was thawed for plate enumeration. Briefly, a 1  mL 
aliquot was centrifuged for 5  min at 5000 ×g and re-
suspended in 1 mL of PBS containing 100 µg/mL Dap 
(PBS/Dap). The resulting vectors were serially diluted 
and plated in duplicate on BHI/Kan/Dap agar. Colony 
counts at each dilution were averaged to calculate 
overall CFU/mL and represented a viable concentra-
tion for vector stocks of anti-AIV/NP, anti-AIV/PA, 
and parent/pmbv43/CEQ (anti-AIV/scramble). This 
system allowed a live inoculum stock to be directly 
used in all future assays.
Analysis of β(1) integrin expression in LMH cells
Avian tissues represent a novel target for tkRNAi, there-
fore, it was important to verify the presence of β(1) inte-
grin receptors on the surface of LMH cells under normal 
conditions (uninfected) and post AIV infection. Total 
RNA was extracted from uninfected (normal growth 
conditions) and LMH cells infected six and 24 hpi with 
H8N4 virus. Chicken β-actin was used as an internal 
control for β(1) integrin expression. Primers and cycling 
conditions for chicken β-actin and β(1) integrin were 
previously published (Caprile et  al. 2009). First strand 
cDNA was synthesized and conventional PCR amplifi-
cation was completed using a 25  µL reaction contain-
ing: 0.075  µg of cDNA, 0.8  mM dNTPs (total), 1.6  mM 
MgCl2, 2.5  µL 10× Amplitaq Gold Buffer II, 0.8  U Taq 
DNA polymerase (Life Technologies), and 0.4 µM of each 
primer. PCR products were analyzed by 2 % agarose gel 
electrophoresis.
Optimal tkRNAi vector concentration
LMH cells were seeded in 24-well plates  1  day prior to 
invasion to reach 80  % confluency. Anti-AIV/scram-
ble vector was serially diluted 1:4 in invasion medium 
(Waymouth’s, 2 mM l-glutamine, 50 µg/ml of Dap) from 
5 × 107 to 7.8 × 105 CFU/mL. Cells were washed twice 
with invasion medium before 1  mL of anti-AIV/scram-
ble vector at each dilution was added to an appropriate 
well, in triplicate, and allowed to incubate for 2 h. Each 
plate included an untreated well (Waymouth’s complete 
medium) and a mock-invasion well (invasion medium 
only). After 2  h incubation, invasion medium was aspi-
rated and wells were washed twice before fresh Way-
mouth’s complete medium was replaced. At multiple 
time points post invasion (24–48 h), vector cytotoxicity 
was assessed using visual signs of CPE and crystal violet 
staining as described above in “cells and viruses”, com-
pared to the untreated control wells. The maximum anti-
AIV/scramble vector concentration allowable, without 
inducing CPE, was selected for all subsequent invasion 
assays in LMH cells.
Table 2 The AIV strain and  corresponding virus gene tar-
geted by the NP or PA siRNA construct
Virus strain Subtype Gene Accession
A/chicken/Texas/473‑2/2010 H6N2 NP KM244053
A/turkey/Colorado/235497/2003 H8N4 NP GU051910
A/chicken/Texas/473‑2/2010 H6N2 PA KM244051
A/turkey/Colorado/235497/2003 H8N4 PA GU051912
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Intracellular uptake of tkRNAi vectors
Using standard transformation methods, the anti-AIV/
scramble vector was co-transformed with the red fluo-
rescent protein (RFP) prokaryotic expression vector, 
pE2-Crimson (Clontech, Mountain View, USA), into 
CEQ221 competent E. coli cells as previously described 
(Bevis and Glick 2002) and live inoculum stocks were 
generated and enumerated. LMH cells were seeded in 
8-well chamber slides 1  day prior to invasion. On the 
day of vector invasion, a 1 mL aliquot of the RFP-vector 
was prepared and serially diluted 1:4 in invasion medium 
starting at 5  ×  107 and ending at 7.8  ×  105 CFU/mL. 
LMH cells were prepared for invasion and 1 mL of RFP-
vector at each dilution was added. After 2 h, wells were 
rinsed twice to remove unbound RFP-vector and fresh 
complete medium was replaced. To visualize RFP expres-
sion using fluorescent microscopy, cells were rinsed twice 
with PBS and fixed using ProLong Gold Antifade Rea-
gent with 4′,6-diamidino-2-phenylindole (DAPI) (Life 
Technologies). Images were captured using the Eclipse 
Ti inverted fluorescent microscope (Nikon Instru-
ments Inc., Melville, USA) at 40× magnification. DAPI 
stained nuclei associated with RFP signal were noted. 
To verify intracellular RFP-vector invasion and deter-
mine invasion efficiencies, LMH cells were detached at 
20 and 36 h post invasion using trypsin and centrifuged 
at 500 ×g for 5 min. Supernatant was removed and cells 
were re-suspended in 2 mL cold PBS containing 5 % FBS. 
Intracellular RFP fluorescence was detected in the red 
(592–671/39 nm) channel by flow cytometry. Acquisi-
tion and analysis was performed on a Beckman Coulter 
MoFlo Astrios Flow Cytometer using Summit Software 
6.1. One untreated (Waymouth’s complete medium), one 
mock-invasion control (invasion medium only) and one 
non-RFP invasion control well (anti-AIV/scramble vector 
at 3.1 × 106 CFU/mL) was always included.
Anti‑AIV vector invasion and virus infection
LMH cells were seeded one day prior to invasion in 
24-well plates to allow cell monolayers to reach 80  % 
confluency. On the day of vector invasion, 1  mL stock 
aliquots of anti-AIV/NP, anti-AIV/PA, and anti-AIV/
scramble vector were thawed, centrifuged, and re-sus-
pended in PBS/Dap. Vectors were diluted and the LMH 
cells were prepared for the invasion assay. Triplicate 
wells of the above vectors plus a cocktail of anti-AIV/
NP +  anti-AIV/PA vector (anti-AIV/cocktail) were pre-
pared. Control wells were also included in triplicate 
(mock-invasion and untreated). After 2  h incubation, 
LMH cells were washed and fresh Waymouth’s complete 
medium was replaced.
Twenty four hours post vector invasion the LMH cells 
were prepared for infection by removing the growth 
medium and washing with inoculation medium (IM) 
containing 0.25  μg/mL L-1-Tosylamide-2-phenylethyl 
chloromethyl ketone (TPCK) treated trypsin (Sigma-
Aldrich, St. Louis, USA), 3  % bovine serum albu-
min (BSA) (Gemini Bio-Products, Sacramento, USA), 
2  mM  l-glutamine, 100  Units/mL penicillin and 1  mg/
mL streptomycin in Waymouth’s MB. The wash was 
removed and IM containing either H8N4 or H6N2 (MOI 
of 0.01) was added. Plates were incubated on a rocking 
platform for 1 h before removing the virus and replacing 
with fresh IM. Cell culture supernatants were harvested 
48 hpi, centrifuged at 10,000 ×g for 10 min at room tem-
perature, and frozen at −80  °C. For each virus tested, 
samples, including positive controls (AIV infected), nega-
tive controls (untreated LMH cells), and mock-invasion 
controls (mock-invasion + AIV infected) were included 
in triplicate wells.
Evaluation of infectious virus titer
LMH cell culture supernatants containing infectious 
virus were quantitated by TCID50 on MDCK cells and 
titer was expressed as the TCID50/mL. Briefly, conflu-
ent monolayers of MDCK cultures growing in 96 well 
plates were inoculated with 100  µL/well of virus super-
natant that was ten-fold serially diluted in MEM/EBSS, 
2  mM  l-glutamine, 3  % BSA, 0.5  % sodium pyruvate, 
0.5  % MEM-NEAA, 100  U/mL penicillin and 1  mg/mL 
streptomycin, containing 1 µg/mL TPCK treated trypsin. 
Each dilution from 1:10 to 1:1012 was added in triplicate. 
At 48 hpi cells were fixed and stained with 0.1  % crys-
tal violet and wells with CPE were scored as positive for 
virus growth. The TCID50/mL was calculated by the Reed 
and Muench mathematical technique (Reed and Muench 
1938).
Statistical analysis
All invasion experiments were repeated three times 
and on three different days. Due to observed changes 
in viral titers between different experimental days (data 
not shown), multiple linear regression analysis was 
used to adjust for variability between experimental days 
and compare adjusted mean log10 TCID50/mL values 
between vector treated and positive control (PC) samples 
(p < 0.05). Statistical analyses were performed using the 
data analysis and statistical software STATA 10 IC (Stata-
Corp, College Station, USA).
Results
Design of effective shRNAs
BLAST screening revealed a lack of sequence comple-
mentarity (0  %) between the NP and PA siRNA seed 
regions and any known chicken gene. The wide range of 
genetic variation among different strains and subtypes 
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of AIV makes it difficult to design siRNAs that can 
remain effective as antivirals. Therefore, it is important 
to design siRNAs targeting highly conserved sequences 
observed across many different strains, including HPAI 
viruses. Both siRNA sequences had 100  % alignment 
against >10,000 type A influenza viruses, including those 
isolated from swine, avian, equine, canine, and humans. 
These query matches included pathogenic H5, H9, and 
H7 subtypes isolated as recently as 2015. The potency of 
these two unique siRNA sequences has been extensively 
evaluated in previous work using traditional transfec-
tion techniques (Abrahamyan et al. 2009; Ge et al. 2003, 
2004; Khantasup et al. 2014; Li et al. 2005; Sui et al. 2009; 
Tompkins et al. 2004).
Verifying intracellular uptake and optimal vector 
concentration in avian cells
The use of chicken primary hepatocellular carcinoma epi-
thelial cells was not intended to represent a model for epi-
thelial cells of the avian respiratory system. The tkRNAi 
system is not specific for respiratory mucosal epithelia; it 
broadly targets all mucosal epithelia. While tkRNAi deliv-
ery has been well documented in mammalian mucosal 
epithelial cells, this study reports the first time tkRNAi 
has been evaluated in avian cells. LMH cells were cho-
sen to broadly represent an avian tissue model to verify 
that chicken β(1) integrin recognizes and interacts with 
invasion, the antigen expressed by the tkRNAi deliv-
ery vector and required for intracellular uptake. Moreo-
ver, LMH cells were utilized for this initial in vitro proof 
of concept work because they represent a commercially 
available chicken cell line with good reproducibility, they 
are specifically intended for transfection studies, they rep-
resent an appropriate avian tissue cell for AIV infection 
(Shinya et  al. 1995;  Swayne and Pantin-Jackwood 2006), 
and as epithelial hepatocytes, they represent appropri-
ate mucosal epithelial cells to test tkRNAi vector uptake. 
Therefore, the expression of β(1) integrin in LMH cells 
when uninfected and post AIV infection was validated 
(Fig. 2). The maximum anti-AIV/scramble concentration 
allowable, without inducing CPE indicative of cytotox-
icity, was 7.8  ×  105  CFU/mL. Therefore, all subsequent 
experiments adopted this vector concentration. Fluores-
cent microscopy demonstrated intracellular expression of 
the RFP-vector in LMH cells at two and 24 h post inva-
sion (Fig. 3). Flow cytometry further verified intracellular 
RFP-vector expression at 20 and 36 h post invasion with 
7.8 ×  105 CFU/mL. The tkRNAi invasion efficiencies in 
LMH cells were calculated to be 74.1 and 75.7 %, respec-
tively (Fig. 4). Together, these results indicated the tkRNAi 
delivery platform was appropriate for avian cells.  
Anti‑AIV vector antiviral activity in avian cells
Previous work has demonstrated inhibition of viral NP 
and PA mRNA transcripts using RT-qPCR following 
transfection with the same 19nt NP and PA siRNA con-
structs utilized in this work (Abrahamyan et  al. 2009; 
Ge et al. 2003; Khantasup et al. 2014; Li et al. 2005; Sui 
et  al. 2009). The objective of this current work was to 
show inhibition of infectious viral particle shedding. 
RT-qPCR does not differentiate between infectious and 
non-infectious virus, however, the TCID50 assay allows 
for the quantification of infectious viral particles. There-
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Fig. 2 mRNA expression of β‑actin and β(1) integrin in LMH cells cul‑
tured in normal growth medium (GM), inoculation medium without 







Fig. 3 Vector uptake by chicken LMH cells assessed at two and 24 h 
post invasion with the anti‑AIV/scramble vector tagged with RFP. LMH 
cells incubated with the RFP‑vector at two doses (high = 7.8 × 105 
CFU/mL and low = 1.95 × 105 CFU/mL). Nuclei were stained with 
DAPI. Magnification, X40
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have been validated using RT-qPCR in avian and mam-
malian models against AIV and to aid in demonstrat-
ing the efficacy for inhibiting infectious virus, LMH cell 
culture supernatants containing shed virus were quan-
titated by TCID50 on MDCK cells and infectious titer 
was expressed as the TCID50/mL. There were no sta-
tistically significant differences in adjusted mean viral 
titers between PC and mock-invasion samples (data not 
shown); therefore, PC samples were used to make statis-
tical comparisons to the vector treated samples. The 95 % 
confidence interval (CI) for the adjusted mean viral titers 
were calculated and represent the magnitude of vari-
ability between viral titers on different experimental days 
and across replicates (Table  3). The adjusted mean viral 
titers between anti-AIV vector treated and untreated 
PC samples were compared across all experimental days 
(Table  3). These results indicated the level of antiviral 
activity was more pronounced against the H8N4 virus. 
However, in all experimental sets and for both H8N4 and 
H6N2, the cocktail vector resulted in significantly lower 
viral titers compared to the corresponding PC titers, with 
log10 reductions ranging from 1.9–4.0.
Discussion
RNAi approaches have been used to demonstrate the 
antiviral activity of siRNAs against influenza viruses 
and report various degrees of viral inhibition in mul-
tiple subtypes tested (Ge et  al. 2003, 2004; Jiao et  al. 
2013; Khantasup et al. 2014; Li et al. 2005; Stoppani et al. 
2015; Tompkins et  al. 2004; Zhou et  al. 2007, 2008). In 
one study, siRNAs targeting NP and PA inhibited the 
lab-adapted PR8 virus (Ge et  al. 2003). In mice experi-
ments, NP and PA siRNAs/shRNAs have inhibited 
multiple type A influenza subtypes, including H5N1 
and mouse-adapted H1N1, H7N7 and H9N2 (Ge et  al. 
2004; Tompkins et  al. 2004; Zhou et  al. 2008). A recent 
siRNA study, targeting NP, reports inhibition against AIV 
(H7N1) and swine influenza (H1N2, H3N2, and H1N1 
strains) (Stoppani et  al. 2015). Critically, in all of these 
studies, viral reductions represent those associated with 
siRNA/shRNA silencing using traditional RNAi delivery 
approaches. Our work represents the first time tkRNAi 
has been assessed both as an shRNA delivery vehicle to 
avian cells and as an antiviral for influenza virus. If the 
in vitro success of this antiviral validated in this current 
work can be demonstrated with future in  vivo studies, 
this antiviral technique has the potential to attain clinical 
relevance by providing a safe and efficacious method of 
delivering siRNAs to target tissues, including avian epi-
thelium, without inducing cytotoxicity. Nonrelated work 
has successfully used this RNAi delivery approach to tar-
get cancer genes (Buttaro and Fruehauf 2010; Kruhn et al. 
RFP-vector 
treated LMH














Fig. 4 Flow cytometry data for LMH cells not treated with the RFP‑vector (LMH only), LMH cells stably expressing RFP‑vector (RFP‑vector treated 
LMH), and RFP‑vector only. LMH cells were treated with 7.8 × 105 CFU/mL RFP‑vector and intracellular RFP expression was assessed at 20 and 36 h 
post vector invasion. RFP fluorescent signal was normalized to the RFP‑vector only expression and invasion efficiencies (%) are depicted as number 
of cells expressing RFP out of the total number of cells counted
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2009; Xiang et al. 2006; Zhao et al. 2005). Cequent Phar-
maceuticals (now Marina Biotech, Bothell, WA, USA) 
recently developed a therapeutic based on the tkRNAi 
platform (CEQ508), which is currently in clinical testing 
for the treatment of Familial Adenomatous Polyposis in 
humans.
As was demonstrated in our work and in previous 
studies, there were variations in the level of viral inhi-
bition observed when the same siRNA construct was 
used against different AIVs. This can be explained in sev-
eral ways. It is possible that in different AIVs these tar-
get mRNA sequences correspond with slightly different 
functions and might interact differently with host factors 
or interact with entirely separate host factors, all result-
ing in slightly altered siRNA potency. Directly measur-
ing anti-AIV vector knockdown of NP and PA could 
help explain the observed variation in antiviral activity 
between viruses. However, our outcome of interest was 
the ability of these anti-AIV vectors to inhibit infec-
tious viral shedding. As such, quantitating infectious 
viral titers using the TCID50 assay was an appropriate 
end-point analysis for this work. Additionally, including 
the anti-AIV/scramble vector served as a method of dif-
ferentiating NP and PA shRNA antiviral activity associ-
ated with targeting the NP and PA viral genes from any 
non-specific viral inhibition caused by the bacterial vec-
tor itself. In all experiments, and for both viruses tested, 
antiviral activity associated with the NP and PA spe-
cific anti-AIV vectors was more potent compared to the 
scramble vector alone.
The scramble vector had less profound antiviral activity, 
but it did reduce infectious AIV titers. There is a possi-
ble explanation for this observation. The innate immune 
response is part of the host’s early defense mechanism. 
Toll-like receptors (TLRs) play a key role in the innate 
response by recognizing and binding bacterial compo-
nents, including endotoxins like lipopolysaccharide (LPS), 
which act as immune enhancers (Bessler et al. 1990). Non-
pathogenic E. coli bacteria deliver these anti-AIV vectors; 
therefore, it is not surprising that the extracellular pres-
ence of bacterial endotoxins would be detected, likely via 
TLR-4 recognition (Schoen et al. 2004). In this case, LPS 
could act like a vaccine adjuvant, thereby stimulating the 
innate response prior to AIV infection and mounting an 
additional level of viral protection.
This work was necessary and provided in  vitro proof-
of-concept demonstrating both successful delivery and 
the antiviral potential of these novel anti-AIV vectors 
against AIV in an avian cell model. Further work is needed 
to determine if these antiviral vectors would reduce AIV 
shedding in poultry. As such, findings from this work have 
been translated into ongoing efforts aimed at assessing 
efficacy in experimentally challenged chickens. This novel 
antiviral could represent a more effective and universal 
control method for AIV in poultry. These vectors were 
engineered for targeted siRNA delivery to mucosal epithe-
lium, including respiratory tissues, and could be applied 
to large populations of birds using a spray or nebulization 
technique. Therefore, this antiviral approach could rep-
resent a scalable and clinically applicable technology for 
Table 3 Anti-AIV vector protection in chicken LMH cells as measured by log10 and fold-reductions in viral shedding titers 
compared to untreated controls
Mean viral titers were adjusted by day, using experimental day as a fixed effect
a Expressed as mean log10 TCID50/mL adjusted by day
b Comparing adjusted mean log10 TCID50/mL from treated to untreated PC samples (p < 0.05)
c Log10 reduction in mean infectious titer compared to untreated control
d Fold reduction in infectious titer (geometric mean) compared to untreated control
Sample n Adjusted 
meana 
(treated)








H8N4 virus MOI 0.01
 Anti‑AIV/NP 9 1.1 (0.0, 2.6) 4.9 (3.7, 6.2) <0.001 3.8 6310
 Anti‑AIV/PA 9 3.0 (2.1, 3.8) 5.5 (4.6, 6.4) <0.001 2.5 316
 Anti‑AIV/cocktail 9 0.9 (0.0, 2.1) 4.9 (3.9, 6.0) <0.001 4.0 10,000
 Anti‑AIV/scramble 10 2.8 (2.0, 3.5) 4.9 (4.1, 5.8) <0.001 2.1 126
H6N2 virus MOI 0.01
 Anti‑AIV/NP 9 4.7 (3.1, 6.2) 6.3 (4.8, 8.0) 0.043 1.6 39.8
 Anti‑AIV/PA 9 4.9 (3.6, 6.2) 6.3 (4.8, 7.9) 0.031 1.4 25.1
 Anti‑AIV/cocktail 9 4.4 (3.0, 5.9) 6.3 (4.9, 7.8) 0.013 1.9 79.4
 Anti‑AIV/scramble 9 5.5 (4.6, 6.3) 6.3 (5.3, 7.4) 0.053 0.8 6.3
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avian and human influenza and a prototype for RNAi-
based antivirals against other viruses that infect mucosal 
tissues.
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